Gracell Biotechnologies (shanghai) Co., Ltd.

This study is testing a new type of personalized cell therapy called GC012F for people with multiple myeloma that has come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, genetically modify them in a lab to better hunt cancer,…

This early-stage study is testing an experimental injection called GC012F in adults with severe systemic lupus erythematosus (lupus) that hasn't improved with standard treatments. The main goals are to check if the treatment is safe and to find the right dose. Researchers will al…

This early-stage study is testing a new type of treatment called GC012F, a CAR-T cell therapy, for Chinese adults with AL amyloidosis that has come back or hasn't responded to prior treatments. The main goals are to find a safe and tolerable dose and to see if the therapy can hel…